BFM
MRKR icon

Boston Financial Management’s Marker Therapeutics MRKR Stock Holding History

Boston Financial Management’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-6,105
Closed -$206K – 270
2018
Q1 		$206K Buy
+6,105
New +$216K 0.01% 255

Other funds holding MRKR

DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MA
MYDA Advisors Woodmere, New York $608M AUM 77.08% 1-Year Est. Return
NRS
Neville Rodie & Shaw New York $1.55B AUM 46.95% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Boston Financial Management's MRKR Position: Q2 2018 in Review

Boston Financial Management sold out of Marker Therapeutics (MRKR) in Q2 2018, closing a stake of 6,105 shares — an estimated $206K sold.

Boston Financial Management first reported a position in MRKR in Q1 2018 and held it in 1 quarter. The position peaked at $206K in Q1 2018. 27 funds tracked by Wall St. Rank hold MRKR as of Q2 2018.

  • Boston Financial Management reported no remaining Marker Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Boston Financial Management sold 6,105 Marker Therapeutics shares in Q2 2018, an estimated $206K.
  • Boston Financial Management first reported a position in Marker Therapeutics in Q1 2018 and held it in 1 quarter.
  • Boston Financial Management's Marker Therapeutics position peaked at $206K in Q1 2018.
  • 27 funds tracked by Wall St. Rank held Marker Therapeutics as of Q2 2018.

Based on Boston Financial Management's 13F filing for Q2 2018, filed 3 Aug 2018.